公开(公告)号：US20180193531A1

公开(公告)日：2018-07-12

申请号：US15895674

申请日：2018-02-13

Applicant: Tricol Biomedical, Inc.

Inventor： Barbara McGrath ,  Simon McCarthy ,  Sam Kuhn ,  Alysha Wold ,  Michael Stolten ,  Amanda Bennett

IPC: A61L27/58 ,  C08L89/06 ,  C08B37/08 ,  C08L5/08 ,  A61L27/26 ,  G01N33/50

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

公开(公告)号：US11229724B2

公开(公告)日：2022-01-25

申请号：US16892865

申请日：2020-06-04

Applicant: Tricol Biomedical, Inc.

Inventor： Barbara McGrath ,  Simon McCarthy ,  Sam Kuhn ,  Alysha Wold ,  Michael Stolten ,  Amanda Bennett

IPC: A61L27/26 ,  A61L27/58 ,  C08L5/08 ,  C08B37/08 ,  A61K47/36 ,  A61K9/00 ,  A61K49/00 ,  G01N33/50 ,  G01N33/68 ,  A61L27/20 ,  C08L89/06

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

公开(公告)号：US11160901B2

公开(公告)日：2021-11-02

申请号：US15565388

申请日：2016-04-11

Applicant: Tricol Biomedical, Inc.

Inventor： Maggie Bush ,  Sam Kuhn ,  Simon McCarthy

IPC: A61L24/08 ,  A61L24/00 ,  C08L5/08 ,  A61K47/36 ,  A61K47/10 ,  A61K31/155 ,  A61K47/14 ,  A61K47/02 ,  A61K31/785 ,  A61K47/12 ,  A61K9/06

Abstract: An aqueous chitosan gel system of novel non-scarring, non-interfering, transparent, stable, solubilized chitosan that controls bleeding is described herein. The aqueous chitosan gel system can comprise water, chitosan, an acid, a plasticizer, a rheology modifying agent, an antioxidant stabilizer, an alcohol, and a multi-valent salt. Additional components of the aqueous chitosan gel system can comprise a bifunctional organic acid, a tnfunctional organic acid, a multi-functional organic acid, a phosphoric acid, a polyphosphoric acid and a salt.

公开(公告)号：US10709817B2

公开(公告)日：2020-07-14

申请号：US15895674

申请日：2018-02-13

Applicant: Tricol Biomedical, Inc.

Inventor： Barbara McGrath ,  Simon McCarthy ,  Sam Kuhn ,  Alysha Wold ,  Michael Stolten ,  Amanda Bennett

IPC: A61L27/26 ,  C08L89/06 ,  C08L5/08 ,  G01N33/50 ,  A61L27/58 ,  A61L27/20 ,  C08B37/08 ,  A61K47/36 ,  A61K9/00 ,  A61K49/00 ,  G01N33/68

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

公开(公告)号：US20180169134A1

公开(公告)日：2018-06-21

申请号：US15895677

申请日：2018-02-13

Applicant: Tricol Biomedical, Inc.

Inventor： Simon McCarthy ,  Barbara McGrath ,  Sam Kuhn ,  Jess Kimball ,  Michael Stolten ,  Amanda Bennett

IPC: A61K31/722 ,  A61K9/19 ,  A61K9/16 ,  A61K47/12 ,  A61K9/70

CPC classification number: A61K31/722 ,  A61K9/1652 ,  A61K9/1694 ,  A61K9/19 ,  A61K9/70 ,  A61K47/12

Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid. Chitosan materials can be mixed in solution with one or more of other hydrophilic polymers to create compositional heterogeneity and pharmaceutical agents to achieve controlled release of the agent(s) from the final forms at the site of application.

公开(公告)号：US09925310B2

公开(公告)日：2018-03-27

申请号：US15371010

申请日：2016-12-06

Applicant: Tricol Biomedical, Inc.

Inventor： Barbara McGrath ,  Simon McCarthy ,  Sam Kuhn ,  Alysha Wold ,  Michael Stolten ,  Amanda Bennett

IPC: A61L27/58 ,  A61L27/26 ,  C08L89/06 ,  C08L5/08 ,  C08B37/08 ,  G01N33/50

CPC classification number: A61L27/58 ,  A61K9/0024 ,  A61K47/36 ,  A61K49/0008 ,  A61L27/20 ,  A61L27/26 ,  A61L2400/04 ,  C08B37/003 ,  C08L5/08 ,  C08L89/06 ,  C08L2201/06 ,  G01N33/5014 ,  G01N33/6869 ,  G01N2333/545 ,  G01N2400/28

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

公开(公告)号：US09846163B2

公开(公告)日：2017-12-19

申请号：US14638770

申请日：2015-03-04

Applicant: Tricol Biomedical, Inc.

Inventor： Barbara McGrath ,  Simon McCarthy ,  Sam Kuhn ,  Alysha Wold ,  Michael Stolten ,  Amanda Bennett

IPC: A61K49/00 ,  G01N33/68 ,  A61L27/20 ,  C08B37/08 ,  A61K47/36 ,  A61L27/26 ,  A61K9/00 ,  C08L5/08

CPC classification number: A61L27/58 ,  A61K9/0024 ,  A61K47/36 ,  A61K49/0008 ,  A61L27/20 ,  A61L27/26 ,  A61L2400/04 ,  C08B37/003 ,  C08L5/08 ,  C08L89/06 ,  C08L2201/06 ,  G01N33/5014 ,  G01N33/6869 ,  G01N2333/545 ,  G01N2400/28

Abstract: The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.

公开(公告)号：US11234998B2

公开(公告)日：2022-02-01

申请号：US16821459

申请日：2020-03-17

Applicant: Tricol Biomedical, Inc.

Inventor： Simon McCarthy ,  Barbara McGrath ,  Sam Kuhn ,  Jess Kimball ,  Michael Stolten ,  Amanda Bennett

IPC: A61K31/722 ,  A61K9/70 ,  A61K47/12 ,  A61K9/16 ,  A61K9/19

Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid. Chitosan materials can be mixed in solution with one or more of other hydrophilic polymers to create compositional heterogeneity and pharmaceutical agents to achieve controlled release of the agent(s) from the final forms at the site of application.

公开(公告)号：US20180110897A1

公开(公告)日：2018-04-26

申请号：US15565388

申请日：2016-04-11

Applicant: Tricol Biomedical, Inc.

Inventor： Maggie Bush ,  Sam Kuhn ,  Simon McCarthy

IPC: A61L24/08 ,  A61L24/00

CPC classification number: A61L24/08 ,  A61K9/06 ,  A61K31/155 ,  A61K31/785 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/36 ,  A61L24/0031 ,  A61L24/0042 ,  A61L2400/04 ,  C08L5/08 ,  C08L1/284

Abstract: An aqueous chitosan gel system of novel non-scarring, non-interfering, transparent, stable, solubilized chitosan that controls bleeding is described herein. The aqueous chitosan gel system can comprise water, chitosan, an acid, a plasticizer, a rheology modifying agent, an antioxidant stabilizer, an alcohol, and a multi-valent salt. Additional components of the aqueous chitosan gel system can comprise a bifunctional organic acid, a tnfunctional organic acid, a multi-functional organic acid, a phosphoric acid, a polyphosphoric acid and a salt.

公开(公告)号：US09925210B2

公开(公告)日：2018-03-27

申请号：US14614316

申请日：2015-02-04

Applicant: Tricol Biomedical, Inc.

Inventor： Simon McCarthy ,  Barbara McGrath ,  Sam Kuhn ,  Jess Kimball ,  Michael Stolten ,  Amanda Bennett

IPC: A61K31/722 ,  A61K9/19 ,  A61K9/16 ,  A61K47/12 ,  A61K9/70

CPC classification number: A61K31/722 ,  A61K9/1652 ,  A61K9/1694 ,  A61K9/19 ,  A61K9/70 ,  A61K47/12

Abstract: The present invention comprises chitosan materials and methods of using carbonic acid for aqueous solubilization of neutralized or pre-treated chitosan gels and provides, among other things, substantially acid salt free composition native final forms without requiring subsequent acid salt elution. The invention includes chitosan-based solid and semi-solid material forms, optionally reinforced with chitosan fibers, such as powders, fibers, films, matrices, sponges, implants, scaffolds, fillers, and hydrogels. Native final forms are produced from chitosan powder solubilized in an aqueous acidic solution, processed to form a high pH hydrated chitosan gel precipitate material that is then neutralized by water washing and re-solubilized substantially to chitosan solution using carbonic acid. Chitosan materials can be mixed in solution with one or more of other hydrophilic polymers to create compositional heterogeneity and pharmaceutical agents to achieve controlled release of the agent(s) from the final forms at the site of application.